文献速递消化系统肿瘤

早发性结直肠癌患者基因组突变模式:一项国际多队列观察性研究

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study.
PubMed 文献 · Lancet Oncol · 2025-07-03

该国际多队列观察性研究分析8国17133例结直肠癌样本,比较早发性(<50岁)与晚发性结直肠癌的基因组突变模式。在超突变型中,早发性组TMB显著高于晚发性组(平均比值1.11),且APC、KRAS、CTNNB1、TCF7L2突变频率升高,BRAF和RNF43降低;在非超突变型中,早发性组仅TP53突变频率升高,BRAF和KRAS等9个基因降低。作者认为结果支持需针对早发性结直肠癌进行特异性分子谱分析以指导临床实践。

要点

  • 超突变型早发性结直肠癌TMB显著高于晚发性(平均比值1.11,95%CI 1.06-1.16;p<0.0001)。
  • 超突变型中早发性APC、KRAS、CTNNB1、TCF7L2突变频率升高,BRAF和RNF43降低。
  • 非超突变型中早发性仅TP53突变频率升高,BRAF和KRAS等9个基因降低。

核心结论

  • 在超突变型结直肠癌中,年轻患者表现出比年老患者更高的突变负荷。
  • 研究揭示超突变型早发性结直肠癌中存在特定体细胞突变的异常积累,该模式可能促成过去数十年早发性结直肠癌发病率令人担忧的上升。
  • 结果支持需要针对早发性结直肠癌的特异性分子谱分析来指导临床实践。

研究设计与样本

  • 观察性研究,分析来自7个队列(MSKCC、Leiden、ARGO、GENIE、SYSUCC、Asan、FUSCC-CRC)的全外显子组测序和临床级靶向测序数据。
  • 纳入年龄≥18岁、确诊结直肠腺癌或黏液腺癌的患者,样本按肿瘤突变负荷(TMB)>15突变/兆碱基定义为超突变型,TMB≤15为非超突变型。
  • 于2024年1月1日至12月31日分析8个国家17133例肿瘤样本(加拿大218、中国3009、法国62、尼日利亚64、韩国44、西班牙250、荷兰281、美国13205)。
  • 17133例中男性9452例(55.2%)、女性7681例(44.8%);白人10174例(59.4%)、亚裔或太平洋岛民3904例(22.8%)、黑人983例(5.7%);早发性结直肠癌4983例(29.1%)。
  • 主要目标为按TMB分组比较早发性与晚发性结直肠癌的基因组突变模式,使用gamma回归评估TMB差异,使用多元逻辑回归和通路富集分析比较突变数据。

主要发现

  • 超突变型结直肠癌中,早发性组TMB显著高于晚发性组(平均比值1.11,95%CI 1.06-1.16;p<0.0001)。
  • 非超突变型结直肠癌中,校正偏度后早发性组TMB显著低于晚发性组(平均比值2.92,95%CI 2.88-2.96;p<0.0001)。
  • 超突变型中早发性组较晚发性组突变频率升高的基因包括APC(75.0% vs 58.6%;OR 2.00,95%CI 1.59-2.51;校正p<0.0001)、KRAS(53.3% vs 32.0%;OR 2.35,95%CI 1.91-2.89;校正p<0.0001)、CTNNB1(31.6% vs 18.0%;OR 2.15,95%CI 1.70-2.72;校正p<0.0001)和TCF7L2(51.2% vs 35.0%;OR 2.01,95%CI 1.62-2.50;校正p<0.0001)。
  • 超突变型中早发性组较晚发性组突变频率降低的基因包括BRAF(15.6% vs 44.2%;OR 0.27,95%CI 0.21-0.35;校正p<0.0001)和RNF43(39.3% vs 53.9%;OR 0.61,95%CI 0.49-0.76;校正p=0.0015)。
  • 非超突变型中早发性组仅TP53突变频率高于晚发性组(79.5% vs 73.7%;OR 1.37,95%CI 1.25-1.50;校正p<0.0001),而BRAF(6.3% vs 8.6%;OR 0.70,95%CI 0.60-0.81;校正p=0.00024)和KRAS(41.1% vs 45.6%;OR 0.83,95%CI 0.77-0.89;校正p=0.00019)等9个基因突变频率降低。

临床怎么用

  • 作者认为,研究结果支持需要针对早发性结直肠癌的特异性分子谱分析来指导临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The increasing incidence of early-onset colorectal cancer (age <50 years; EOCRC) shows a dramatic growing trend globally, while late-onset colorectal cancer (LOCRC) is gradually decreasing. We aimed to characterise the distinct mutational landscape of EOCRC in an effort to inform age-specific clinical management. METHODS: In this observational study, we analysed whole-exome sequencing and clinical-grade targeted sequencing data from seven cohorts (the Memorial Sloan Kettering Cancer Center [MSKCC] cohort [the USA], the Leiden University Medical Center cohort [the Netherlands], the Nigerian African Research Group for Oncology [ARGO] cohort [Nigeria], the Genomics Evidence Neoplasia Information Exchange [GENIE] Project [Canada, France, Spain, and the USA], the Sun Yat-sen University Cancer Center (SYSUCC) cohort [China], the Asan Medical Center cohort [South Korea], and the Fudan University Shanghai Cancer Center-Colorectal Cancer [FUSCC-CRC] cohort [China]) across Canada, China, France, Nigeria, South Korea, Spain, the Netherlands, and the USA. Eligible patients were aged 18 years or older with a confirmed diagnosis of colorectal adenocarcinoma or mucinous adenocarcinoma. Samples were categorised into hypermutated (tumour mutational burden [TMB] >15 mutations per megabase) and non-hypermutated (TMB ≤15 mutations per megabase) groups. We evaluated the TMB difference between EOCRC and LOCRC using gamma regression and compared genomic mutation data between EOCRC and LOCRC using multiple logistic regression and pathway enrichment analysis. The primary study objective was to compare genomic mutational patterns between EOCRC and LOCRC, stratified by TMB groups. FINDINGS: Between Jan 1 and Dec 31, 2024, 17 133 tumour samples from patients with colorectal cancer in eight countries were analysed (Canada [n=218], China [n=3009], France [n=62], Nigeria [n=64], South Korea [n=44], Spain [n=250], the Netherlands [n=281], and the USA [n=13 205]). Among 17 133 patients, 9452 (55·2%) were male, 7681 (44·8%) were female, 10 174 (59·4%) were White, 3904 (22·8%) were Asian or Pacific Islander, 983 (5·7%) were Black, and 4983 (29·1%) had EOCRC. In hypermutated colorectal cancer, EOCRC exhibited a significantly higher TMB compared with LOCRC (mean ratio 1·11 [95% CI 1·06-1·16]; p<0·0001). In non-hypermutated colorectal cancer, EOCRC showed a significantly lower TMB than LOCRC after adjusting for skewness (mean ratio 2·92 [95% CI 2·88-2·96]; p<0·0001). In hypermutated colorectal cancer, a total of 23 genes, including APC (EOCRC 464 [75·0%] of 619 vs LOCRC 891 [58·6%] of 1521; odds ratio [OR] 2·00 [95% CI 1·59-2·51]; adjusted p<0·0001), KRAS (EOCRC 331 [53·3%] of 621 vs LOCRC 488 [32·0%] of 1526; OR 2·35 [95% CI 1·91-2·89]; adjusted p<0·0001), and CTNNB1 (EOCRC 196 [31·6%] of 621 vs LOCRC 274 [18·0%] of 1526; OR 2·15 [95% CI 1·70-2·72]; adjusted p<0·0001), and TCF7L2 (EOCRC 294 [51·2%] of 574 vs LOCRC 489 [35·0%] of 1398; OR 2·01 [95% CI 1·62-2·50]; adjusted p<0·0001), displayed elevated mutation frequencies in EOCRC compared with LOCRC, whereas only BRAF (EOCRC 97 [15·6%] of 621 vs LOCRC 674 [44·2%] of 1526; OR 0·27 [95% CI 0·21-0·35]; adjusted p<0·0001) and RNF43 (EOCRC 225 [39·3%] of 573 vs LOCRC 778 [53·9%] of 1444; OR 0·61 [95% CI 0·49-0·76]; adjusted p=0·0015) were less frequently mutated in EOCRC than in LOCRC. In non-hypermutated colorectal cancer, only TP53 (EOCRC 3468 [79·5%] of 4362 vs LOCRC 7825 [73·7%] of 10 624; OR 1·37 [95% CI 1·25-1·50]; adjusted p<0·0001) showed a higher mutation frequency in EOCRC, while nine genes had lower mutation frequencies, including BRAF (EOCRC 274 [6·3%] of 4362 vs LOCRC 909 [8·6%] of 10 624; OR 0·70 [95% CI 0·60-0·81]; adjusted p=0·00024) and KRAS (EOCRC 1794 [41·1%] of 4362 vs LOCRC 4840 [45·6%] of 10624; OR 0·83 [95% CI 0·77-0·89]; adjusted p=0·00019). INTERPRETATION: Within hypermutated colorectal cancer, younger patients exhibited a higher mutational burden than older patients. Our study reveals an abnormal accumulation of distinct somatic mutations in hypermutated EOCRC, the pattern of which might be contributing to the alarming rise in the incidence of EOCRC over the past decades. Our results support the need for EOCRC-specific molecular profiling to guide clinical practice. FUNDING: National Natural Science Foundation of China and the Shanghai Science and Technology Development Fund.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Li J, Pan Y, Guo F, et al. Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study. Lancet Oncol. 2025. PMID: 40617240. doi:10.1016/S1470-2045(25)00239-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。